Study: Empagliflozin shows mixed results in heart attack patients

FHS
April 8, 2024
5:21 pm

Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiology’s Annual Scientific Session.

Astellas agrees to take over Propella Therapeutics for $175m

Share this article Astellas plans to fund the acquisition of Propella using cash on hand. Credit: JHVEPhoto / Shutterstock.com. Astellas Pharma has signed an agreement for

November 16, 2023

Body dissatisfaction at age 11 may increase depression risk by age 14

Body dissatisfaction at age 11 is linked to increased risk of depression by age 14, finds a new longitudinal study led by UCL researchers.

December 14, 2023

Rapid increase seen in the diagnosis and treatment of perinatal mental health problems

Mental health issues during pregnancy or the first year of parenthood have a much greater chance of getting detected and treated now than just over

April 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.